Focused On-demand Libraries - Receptor.AI Collaboration


Explore the Potential with AI-Driven Innovation

This extensive focused library is tailor-made using the latest virtual screening and parameter assessment technology, operated by the Receptor.AI drug discovery platform. This technique is more effective than traditional methods, offering compounds with improved activity, selectivity, and safety.


Our selection of compounds is from a large virtual library of over 60 billion molecules. The production and distribution of these compounds are managed by Reaxense.


Contained in the library are leading modulators, each labelled with 38 ADME-Tox and 32 physicochemical and drug-likeness qualities. In addition, each compound is illustrated with its optimal docking poses, affinity scores, and activity scores, giving a complete picture.


Our top-notch dedicated system is used to design specialised libraries.


 

Fig. 1. The screening workflow of Receptor.AI

By deploying molecular simulations, our approach comprehensively covers a broad array of proteins, tracking their flexibility and dynamics individually and within complexes. Ensemble virtual screening is utilised to take into account conformational dynamics, identifying pivotal binding sites located within functional regions and at allosteric locations. This thorough exploration ensures that every conceivable mechanism of action is considered, aiming to identify new therapeutic targets and advance lead compounds throughout a vast spectrum of biological functions.


Several key aspects differentiate our library:


  • Receptor.AI compiles an all-encompassing dataset on the target protein, including historical experiments, literature data, known ligands, and structural insights, maximising the chances of prioritising the most pertinent compounds.

  • The platform employs state-of-the-art molecular simulations to identify potential binding sites, ensuring the focused library is primed for discovering allosteric inhibitors and binders of concealed pockets.

  • Over 50 customisable AI models, thoroughly evaluated in various drug discovery endeavours and research projects, make Receptor.AI both efficient and accurate. This technology is integral to the development of our focused libraries.

  • In addition to generating focused libraries, Receptor.AI offers a full range of services and solutions for every step of preclinical drug discovery, with a pricing model based on success, thereby reducing risk and promoting joint project success.


PARTNER
Receptor.AI
 
UPACC
P56199

UPID:
ITA1_HUMAN

ALTERNATIVE NAMES:
CD49 antigen-like family member A; Laminin and collagen receptor; VLA-1

ALTERNATIVE UPACC:
P56199; B2RNU0

BACKGROUND:
The protein Integrin alpha-1, known for its alternative names such as Laminin and collagen receptor and VLA-1, is a receptor that binds to laminin and collagen. This binding is essential for the negative regulation of EGF-stimulated cell growth, mediated through its recognition of the G-F-P-G-E-R sequence in collagen.

THERAPEUTIC SIGNIFICANCE:
Exploring the functionalities of Integrin alpha-1 reveals its potential in developing therapeutic strategies. Its critical role in cell adhesion and growth regulation underscores its therapeutic potential, despite the current lack of direct association with specific diseases.

Looking for more information on this library or underlying technology? Fill out the form below and we will be in touch with all the details you need.